Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 11/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882614 | 0.81 | MAPK1 (0.51) | ALDH1A1SYK | |
| SCHEMBL4741655 | 0.80 | LMNA (0.42) | CYP11B1CYP11B2ATMP2RX3GRM5 | |
| SCHEMBL4745801 | 0.78 | ALDH1A1 (0.42) | CYP11B1CYP11B2ATMGRM5ALDH1A1 | |
| SCHEMBL4745855 | 0.78 | ALDH1A1 (0.42) | ATMGRM5ALDH1A1SIRT2SIRT1 | |
| SCHEMBL4741924 | 0.77 | ALDH1A1 (0.41) | CYP11B1CYP11B2ATMGRM5ALDH1A1 | |
| SCHEMBL18211758 | 0.77 | HDAC1 (0.38) | ALDH1A1SYK | |
| SCHEMBL4744314 | 0.75 | CYP11B1 (0.49) | CYP11B1CYP11B2ATMP2RX3GRM5 | |
| SCHEMBL30581055 | 0.75 | ATM (0.50) | CYP11B1CYP11B2ATMALDH1A1ALPL | |
| SCHEMBL29073767 | 0.75 | ATM (0.50) | CYP11B1CYP11B2ATMALDH1A1ALPL | |
| SCHEMBL4039719 | 0.74 | MAPK1 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | CYP11B1 1317/4885CYP11B2 1289/4885ATM 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.